Acrivon Therapeutics Reports Officer/Director Changes & Compensation
Ticker: ACRV · Form: 8-K · Filed: Mar 14, 2025 · CIK: 1781174
| Field | Detail |
|---|---|
| Company | Acrivon Therapeutics, Inc. (ACRV) |
| Form Type | 8-K |
| Filed Date | Mar 14, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, compensation, governance
Related Tickers: ACRV
TL;DR
Acrivon (ACRV) filed an 8-K detailing board/exec changes and compensation.
AI Summary
Acrivon Therapeutics, Inc. filed an 8-K on March 14, 2025, reporting on events as of March 11, 2025. The filing primarily concerns the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for these officers. It also includes financial statements and exhibits.
Why It Matters
Changes in a company's board of directors and executive officers, along with details on their compensation, can signal shifts in strategic direction or governance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal shifts that may impact future performance.
Key Players & Entities
- Acrivon Therapeutics, Inc. (company) — Registrant
- March 11, 2025 (date) — Date of earliest event reported
- March 14, 2025 (date) — Date of report
- 001-41551 (company) — SEC File Number
FAQ
What specific changes occurred regarding directors or officers?
The filing indicates events related to the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
What is the primary purpose of this 8-K filing?
The primary purpose is to report on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements, as well as to file financial statements and exhibits.
When were the events reported in this filing effective?
The earliest event reported was effective as of March 11, 2025.
What is Acrivon Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 480 Arsenal Way, Suite 100, Watertown, Massachusetts 02472.
What is the SEC file number for Acrivon Therapeutics, Inc.?
The SEC file number for Acrivon Therapeutics, Inc. is 001-41551.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 14, 2025 regarding Acrivon Therapeutics, Inc. (ACRV).